[HTML][HTML] Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial

E Basch, AM Deal, MG Kris, HI Scher… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose There is growing interest to enhance symptom monitoring during routine cancer
care using patient-reported outcomes, but evidence of impact on clinical outcomes is limited …

Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment

E Basch, AM Deal, AC Dueck, HI Scher, MG Kris… - Jama, 2017 - jamanetwork.com
Methods| The study was approved by the Memorial Sloan Kettering institutional review
board and written informed consent was obtained from participants. Consecutive patients …

Cellular senescence promotes adverse effects of chemotherapy and cancer relapse

M Demaria, MN O'Leary, J Chang, L Shao, SU Liu… - Cancer discovery, 2017 - AACR
Cellular senescence suppresses cancer by irreversibly arresting cell proliferation.
Senescent cells acquire a proinflammatory senescence-associated secretory phenotype …

[HTML][HTML] Cardiac toxicity after radiotherapy for stage III non–small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy

K Wang, MJ Eblan, AM Deal, M Lipner… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose The significance of radiotherapy (RT)–associated cardiac injury for stage III non–
small-cell lung cancer (NSCLC) is unclear, but higher heart doses were associated with …

[HTML][HTML] Monitoring tumorigenesis and senescence in vivo with a p16INK4a-luciferase model

CE Burd, JA Sorrentino, KS Clark, DB Darr… - Cell, 2013 - cell.com
Monitoring cancer and aging in vivo remains experimentally challenging. Here, we describe
a luciferase knockin mouse (p16 LUC), which faithfully reports expression of p16 INK4a, a …

Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy

SS Shachar, AM Deal, M Weinberg, KA Nyrop… - Clinical Cancer …, 2017 - AACR
Purpose: Severe skeletal muscle (SM) loss (sarcopenia) is associated with poor cancer
outcomes, including reduced survival and increased toxicity. This study investigates SM …

Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer

HK Sanoff, AM Deal, J Krishnamurthy… - Journal of the …, 2014 - academic.oup.com
Background Senescent cells, which express p16 INK4a, accumulate with aging and
contribute to age-related pathology. To understand whether cytotoxic agents promote …

Geriatric assessment-identified deficits in older cancer patients with normal performance status

TA Jolly, AM Deal, KA Nyrop, GR Williams… - The …, 2015 - academic.oup.com
Background. We investigated whether a brief geriatric assessment (GA) would identify
important patient deficits that could affect treatment tolerance and care outcomes within a …

Sarcopenia as a predictor of complications and survival following radical cystectomy

AB Smith, AM Deal, H Yu, B Boyd, J Matthews… - The Journal of …, 2014 - Elsevier
Purpose Patients undergoing radical cystectomy face substantial but highly variable risks of
major complications. Risk stratification may be enhanced by objective measures such as …

[HTML][HTML] Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive …

TL Rose, MR Harrison, AM Deal… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE To evaluate the safety and efficacy of gemcitabine and cisplatin in combination
with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical …